Aidoc has announced that the US Food and Drug Administration (FDA) has cleared its AI solution for flagging large vessel occlusion (LVO) in head CTA scans, marking Aidoc’s fourth FDA-cleared AI package. Combined with Aidoc’s previously-cleared AI module for flagging and prioritising intracranial haemorrhage, together they provide a comprehensive AI package for the identification and triage of both ischaemic and haemorrhagic stroke in CTs, speeding time to treatment when every minute counts.
“Stroke is the ultimate time-critical condition,” said Marcel Maya, co-chair Department of Imaging, Cedars-Sinai Medical Center, Los Angeles, USA. “Aidoc’s comprehensive stroke package flags both large vessel occlusion and haemorrhages inside our existing workflows, ensuring we can diagnose stroke faster and decide on the best course of treatment. We are already seeing how this has a positive impact on department efficiency and patient length of stay.”
The company acknowledge that improved medical imaging and better treatments have revolutionised stroke care, making it possible to clear occlusions in the brain’s arteries using thrombolysis or mechanical thrombectomy. However, they point to how haemorrhage must be ruled out before administering a thrombolytic agent. The faster the time from door-to-treatment for patients suffering from stroke, the more likely a patient will survive without serious neurological impairment.
Aidoc’s AI solution continuously scans images for both ischaemic and haemorrhagic stroke, automatically moving suspected cases to the top of radiologists’ worklists. The workflow also provides a single context for radiologists to diagnose both LVO and haemorrhage, so they can quickly decide on the most appropriate course of action. Often, patients are diagnosed with stroke in a smaller facility before being moved to a specialist stroke centre for treatment. Aidoc’s combined stroke solution ensures that the diagnosing facility and the stroke centre can work together in a coordinated manner to expedite patient care.
Research performed by the University of Rochester Medical Center showed Aidoc’s ability to reduce turnaround time for emergency room patients with intracranial haemorrhage by 36.6%. Research by Yale-New Haven Hospital confirmed Aidoc’s impact in expediting the time to treatment for these critical cases.